| Literature DB >> 32993739 |
Chaoying Liu1, Peng Liu1, Xiao Jing Zhang1, Wen Qian Li1, Guoyan Qi2.
Abstract
BACKGROUND: Despite the burgeoning literature describing preoperative and postoperative risks of a myasthenic crisis after thymectomy (MCAT) in patients with myasthenia gravis, substantial differences exist in the risk factors identified by previous studies. We conducted a meta-analysis to assess the reported risk factors and MCAT risk.Entities:
Keywords: Meta-analysis; Myasthenia gravis; Myasthenic crisis; Risks; Thymectomy
Mesh:
Year: 2020 PMID: 32993739 PMCID: PMC7526111 DOI: 10.1186/s13019-020-01320-x
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Fig. 1Flow diagram of the literature search and selection process
The basic characteristics of the included study
| Source | Year | Study year | Study design | No. of patients | No. of myasthenic crisis cases | Age at thymectomy | Gender Male/women | Study region | Non-thymomatous/thymoma | Significant risk factors | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kato | 2019 | 2000–2015 | retrospective cohort study | 90 | 14 | median (range) 51.5 (41.3–64.0) | 41/46 | Japan | 33/57 | (15) | 8 |
| Xue | 2017 | 2005–2014 | case-control studies | 127 | 13 | NA | 68/59 | china | 127 | (3),(10) | 8 |
| Zou | 2016 | 2007.06–2013.12 | retrospective cohort study | 541 | 67 | 26.4 ± 11.7/27.06 ± 13.5 | 256/285 | china | NA | (1),(4),(6),(16) | 6 |
| Ando | 2015 | 2000.01–2013.12 | case-control studies | 55 | 10 | median (range) 55 (13–79) | 25/30 | Japan | 30/25 | (1),(17) | 7 |
| Lee | 2015 | 2007.10–2012.03 | case-control studies | 146 | 10 | T/C 25.0 (15.5–48.0)/35.0 (27.0–46.0) | NA | Korea | 105/41 | (12),(18) | 8 |
| Li | 2018 | 2000.01–2013.03 | case-control studies | 176 | 51 | 46.6 ± 11.7 | 90/83 | China | 0/173 | (2),(19) | 9 |
| Yu | 2014 | 1997.03–2012.03 | retrospective cohort study | 178 | 58 | 38.4 ± 13.2 | 95/83 | China | 69/109 | (1),(2),(8) | 8 |
| Choi | 2014 | 1996.01–2009.12 | retrospective cohort study | 49 | 12 | 50.3 ± 12.4 | 23/25 | Korea | 0/49 | (12) | 6 |
| Leuzzi | 2014 | 1995.01–2011.12 | case-control studies | 177 | 22 | 45.8 ± 16.8 | 107/70 | Italy | 53/124 | (1),(3),(4),(14) | 9 |
| Nam | 2011 | 1997.01–2007.12 | retrospective cohort study | 68 | 20 | age at onset 43.6 ± 13.9 | NA | Japan | 28/38 | (1) | 9 |
| Chu | 2011 | 1990–2009 | case-control studies | 243 | 44 | 31.5 ± 15.7 | 124/119 | China | 175/68 | (3),(5),(13) | 5 |
| Liu | 2006 | 1990.01–2006.01 | case-control studies | 176 | 36 | 31 ± 14 | 74/102 | China | 122/54 | (1),(2),(6),(24) | 9 |
| Li | 2016 | 1970.05–2011.05 | case-control studies | 306 | 49 | 31.54 ± 16.37 | 155/151 | China | NA | (1),(2),(5) | 8 |
| Qian | 2016 | 2002.02–2015.06 | case-control studies | 86 | 16 | median (range)47 (25–71) | 37/49 | China | 40/46 | (1),(2),(3) | 8 |
| Li | 2017 | 2008.01 ~ 2015.01 | case-control studies | 63 | 12 | median (range)37 (10–76) | 25/38 | China | 41/22 | (3),(8),(9),(10) | 7 |
| Liu | 2014 | 2011.01–2014.02 | case-control studies | 102 | 42 | T/C 46.7 ± 10.11/39.6 ± 6.41 | 45/57 | China | 36/66 | (3),(5),(11),(12),(20) | 6 |
| Niu | 2013 | 2002.07–2012.07 | case-control studies | 134 | 28 | age at onset 35 (1–82) | 66/68 | China | 69/65 | (3) | 6 |
| Ma | 2011 | 1995.07–2009.12 | case-control studies | 84 | 24 | median (range)42.67 (16—68) | 35/49 | China | 21/63 | (1),(3),(8),(11) | 6 |
| Zhang | 2015 | 2008.06–2014.06 | case-control studies | 58 | 15 | T/C 60.60 ± 6.20/60.7 ± 6.3 | 26/32 | China | 0/58 | (3),(11),(21) | 6 |
| Wang | 2006 | NA | case-control studies | 126 | 13 | median (range)38 (9–62) | 54/72 | China | 56/70 | (1),(3),(7),(22) | 5 |
| Chen | 2007 | 2002.07–2005.12 | case-control studies | 101 | 29 | 33.2 ± 14.67 | 43/58 | China | 33/68 | (1),(3),(4),(13),(23) | 8 |
| Ge | 2019 | 2008.01–2018.01 | retrospective cohort study | 47 | 14 | 40.1 ± 16.7 | 22/25 | China | 24/23 | (11),(13) | 6 |
| Li | 2014 | 2008.01–2013.06 | case-control studies | 198 | 32 | NA | NA | China | 135/63 | (1),(3),(5),(6) | 5 |
| Kanai | 2017 | 2002.01–2014.12 | case-control studies | 275 | 17 | T/C:45.8 ± 16.1/49.2 ± 15.5 | 106/169 | Japan | 145/130 | (2),(12),(14) | 9 |
| Watanabe | 2004 | 1985.01–2002.12 | retrospective cohort study | 122 | 44 | 44 ± 17 | 30/92 | Japan | 93/29 | (2),(7),(9) | 6 |
MG myasthenia gravis;AchR-Ab anti-acetylcholine receptor antibody; POA preoperative anxiety
(1) preoperative MC history (2) preoperative bulbar symptom (3) preoperative Osserman stages (4) postoperative lung infection (5) thymoma (6) preoperative dosage of pyridostigmine bromide (7) preoperative serum AchR-Ab level (nm/L) (8) operation time (9) intraoperative blood loss>1000 ml (10) WHO classification (11) mode of operation (12) preoperative lung function (13) major postoperative complications (14) disease duration before thymectomy (15) Masaoka stage (16) POA (17) unstable MG (18) decremental response of orbicularis oculi (19) incomplete resection (20) general anaesthesia (21) Postoperative medication (22) Potential MC (23) age (24) preoperative lung infection
Significant risk factors associated with MCAT and the results of bias risk assessment
| Significant Risk Factors | No. of studies | No. of MC | No. of total patients | Analysis model | Adjusted OR (95%CI) | Study heterogeneity | Test for overall effect | Begg’s test P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preoperative MC history | 12 | 377 | 2094 | Fixed | 4.13 [3.08, 5.54] | 13.46 | 0.26 | 18 | 9.46 | <0.00001 | 0.034 | |
| without | ref | |||||||||||
| with | ||||||||||||
| Preoperative bulbar symptoms | 8 | 254 | 1443 | Fixed | 3.71 [2.54, 5.42] | 7.55 | 0.37 | 7 | 6.76 | <0.00001 | 0.174 | |
| without | ref | |||||||||||
| with | ||||||||||||
| Preoperative Osserman stages | 10 | 358 | 2040 | Fixed | 4.55 [3.23, 6.13] | 30.74 | 0.0006 | 67 | 9.15 | <0.00001 | 0.64 | |
| I | ref | |||||||||||
| IIa + IIb + III + VI | 2 | 2.57 [1.43,4.61] | 0.01 | 0.94 | 0 | 3.16 | 0.002 | |||||
| IIb + III + VI | 8 | 11.15 [6.88,18.08] | 5.41 | 0.61 | 0 | 9.78 | <0.00001 | |||||
| VI + V | 1 | 1.80 [0.96, 3.36] | NA | NA | NA | 1.84 | 0.002 | |||||
| Postoperative lung infection | 5 | 92 | 448 | Fixed | 6.49 [2.64, 15.98] | 2.39 | 0.5 | 0 | 4.07 | <0.00001 | 0.624 | |
| without | ref | |||||||||||
| with | ||||||||||||
| Thymoma | 5 | 234 | 1390 | Fixed | 2.96 [2.13, 4.13] | 3.63 | 0.3 | 17 | 6.43 | <0.00001 | 0.806 | |
| no | ref | |||||||||||
| yes | ||||||||||||
| Preoperative dosage of pyridostigmine bromide | 4 | 193 | 1103 | Fixed | 3.53 [2.47,5.03] | 4.98 | 0.17 | 40 | 6.94 | <0.00001 | 1 | |
| ≥240 mg | ||||||||||||
| <240 mg | ref | |||||||||||
| Preoperative serum AchR-Ab level (nm/L) | 2 | 27 | 248 | Fixed | 8.74 [3.31, 23.08] | 0.03 | 0.87 | 0 | 3.65 | 0.0003 | 1 | |
| >100 | ||||||||||||
| ≤100 | ref | |||||||||||
| Operation time | 3 | 95 | 325 | Random | 1.18 [0.89, 1.57] | 19.47 | <0.00001 | 90 | 1.13 | 0.26 | 0.296 | |
| Intraoperative blood loss > 1000 ml | 2 | 26 | 185 | Fixed | 15.03 [3.50, 64.50] | 0.03 | 0.87 | 0 | 3.65 | 0.0003 | 1 | |
| >1000 ml | ||||||||||||
| ≤1000 ml | ref | |||||||||||
| WHO classification | 2 | 25 | 190 | Fixed | 15.23 [4.63, 50.13] | 0.22 | 0.64 | 0 | 4.48 | <0.00001 | 1 | |
| non-thymoma and non-invasive thymoma | ref | |||||||||||
| invasive thymoma | ||||||||||||
| Mode of operation | 4 | 66 | 252 | Fixed | 5.88 [2.06,16.80] | 2.09 | 0.55 | 0 | 3.3 | 0.001 | 0.089 | |
| video-assisted thoracoscopy | ref | |||||||||||
| thoracotomy | ||||||||||||
| Preoperative lung function | 5 | 110 | 784 | Fixed | 5.71 [3.11, 10.48] | 3.3 | 0.51 | 0 | 5.62 | <0.00001 | 1 | |
| normal | ref | |||||||||||
| abnormal | ||||||||||||
| Major postoperative complications | 3 | 87 | 391 | Fixed | 33.78 [10.57,107.96] | 1.59 | 0.45 | 0 | 5.94 | <0.00001 | 1 | |
| without | ref | |||||||||||
| with | ||||||||||||
| Disease duration before thymectomy | 2 | 39 | 452 | Fixed | 5.45 [1.96, 15.14] | 0.02 | 0.9 | 0 | 3.26 | 0.001 | 1 | |
| 1983 | 11,345 | |||||||||||